Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in EuropeAlvotech • May 24th, 2023 • Biological products, (no disgnostic substances)
- The agreement includes proposed biosimilars to Simponi® (golimumab), Entyvio® (vedolizumab) and three additional early-stage undisclosed biosimilar candidates
